Man Group’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,455
Closed -$800K 2091
2022
Q1
$800K Buy
1,455
+26
+2% +$15.7K ﹤0.01% 1436
2021
Q4
$944K Sell
1,429
-895
-39% -$684K ﹤0.01% 1344
2021
Q3
$1.95M Sell
2,324
-2,152
-48% -$2.18M 0.01% 1182
2021
Q2
$5.68M Sell
4,476
-701
-14% -$791K 0.02% 826
2021
Q1
$5.68M Buy
5,177
+2,513
+94% +$3.32M 0.03% 629
2020
Q4
$3.8M Buy
+2,664
New +$2.84M 0.02% 946

Other funds holding CDLX

Man Group's CDLX Position: Q2 2022 in Review

Man Group sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 1,455 shares — an estimated $800K sold.

Man Group first reported a position in CDLX in Q4 2020 and held it in 6 quarters. The position peaked at $5.68M in Q2 2021. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.

  • Man Group reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
  • Man Group sold 1,455 Cardlytics shares in Q2 2022, an estimated $800K.
  • Man Group first reported a position in Cardlytics in Q4 2020 and held it in 6 quarters.
  • Man Group's Cardlytics position peaked at $5.68M in Q2 2021.
  • 138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.

Based on Man Group's 13F filing for Q2 2022, filed 15 Aug 2022.